RNAC
Cartesian Therapeutics, Inc.
There isn't enough reported data to score RNAC yet.
RNAC Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
RNAC's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
RNAC PE Valuation
RNAC has no meaningful PE right now: it lost money over the past year.
RNAC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RNAC's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
RNAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2021 | -$20.70 | +$12.90 |
| Q4 2020 | -$20.40 | +$16.20 |
RNAC is still losing money, but far less than before: $4.84 per share over the past year, against $56.10 at its worst in early 2024.
RNAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $78K | -93% |
| Q3 2025 | $452K | +17% |
| Q2 2025 | $298K | -99% |
| Q1 2025 | $1.1M | -81% |
| Q3 2024 | $387K | -94% |
| Q2 2024 | $33.4M | +537% |
| Q1 2024 | $5.8M | -1.7% |
| Q4 2023 | $8.3M | -51% |
RNAC's revenue has slid since its 2022 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -33973% | -31983 points |
| Q4 2025 | -8304% | N/A |
| Q3 2025 | -4661% | -119 points |
| Q2 2025 | -7319% | -7360 points |
| Q1 2025 | -1990% | -1761 points |
| Q3 2024 | -4541% | -4342 points |
| Q2 2024 | 41% | +396 points |
| Q1 2024 | -229% | +81 points |
RNAC's operating margin was −33973% last quarter, down 31983 points from the same quarter a year ago, near the bottom of its range since 2019.
RNAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.2M | -$11.3M |
| Q2 2026 | -$21.4M | -$1.2M |
| Q1 2026 | -$22.2M | +$2M |
| Q4 2025 | -$18.2M | -$10.5M |
| Q3 2025 | -$16.9M | -325% |
| Q2 2025 | -$20.1M | -$4.1M |
| Q1 2025 | -$24.2M | -$7.7M |
| Q4 2024 | -$7.7M | +$15.6M |
RNAC has burned cash in almost every quarter: −$90M over the past year, against −$69M the year before.
RNAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +448K shares |
| 1 year | +17% | +4.3M shares |
| 3 years | +493% | +25.2M shares |
| 5 years | +798% | +26.9M shares |
RNAC has 30M diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
RNAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -7.0x | Net Cash |
| Q3 2022 | -4.1x | Net Cash |
| Q2 2022 | -5.1x | Net Cash |
| Q1 2022 | -8.1x | Net Cash |
RNAC has more cash than debt.
RNAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.5 | Neutral |
| Stochastic | 16.1 | Oversold |
RNAC's weekly RSI is 43 (neutral) and its Stochastic is 16 (oversold).
RNAC PE vs Healthcare Sector
| Metric | RNAC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RNAC has no meaningful PE right now: it lost money over the past year.
RNAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.83 | 6.9% below |
| 20 week MA | $8.07 | 21% below |
| 50 week MA | $7.57 | 16% below |
| 100 week MA | $10.1 | 37% below |
| 200 week MA | $19.2 | 67% below |
RNAC is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
RNAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.7 | $98.1 | +43% |
| 2021 | $98.1 | $107.1 | +9.2% |
| 2022 | $107.1 | $29.4 | -73% |
| 2023 | $29.4 | $20.7 | -30% |
| 2024 | $20.7 | $19.8 | -4.3% |
| 2025 | $19.8 | $6.68 | -66% |
| 2026 YTD | $6.68 | $6.36 | -4.8% |
RNAC has finished four years in a row lower, and it's down 4.8% so far in 2026.